Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
31 January 2024 - 11:42PM
Edgar (US Regulatory)
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
USA
Basel, January 31, 2024
Ladies and Gentlemen:
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat
Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that
Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on January 31, 2024.
Respectfully submitted,
Novartis AG
|
/s/ Karen L. Hale
|
|
/s/ Harry Kirsch
|
|
|
Karen L. Hale
Chief Legal Officer of Novartis
|
|
Harry Kirsch
Chief Financial Officer of Novartis
|
|
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
